retatrutide 4mg ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide - Research Dosing &

Log side effects, energy levels, and mood

Third, real-world data from large patient populations suggests GLP-1 receptor agonist users may have lower rates of certain inflammatory conditions

Phase 2 NEJM titration (still common in research) Phase 2 retatrutide titration schedule Phase Initiation Weeks Weeks 1-4 Weekly Dose 1 mg Phase Early escalation Weeks Weeks 5-8 Weekly Dose 2 mg Phase Mid escalation Weeks Weeks 9-12 Weekly Dose 4 mg Phase High escalation Weeks Weeks 13-16 Weekly Dose 8 mg Phase Maximum Weeks Weeks 17+ Weekly Dose 12 mg Source: Jastreboff et al., NEJM 2023

Clinical Guideline for the Evaluation, Management and Long-Term Care of Obstructive Sleep Apnea in Adults

Each batch of GLP-1/GIP/GLUCAGON 20mg undergoes independent third-party testing to verify identity, purity, and content

Semaglutide can also improve heart failure-related symptoms and inflammation in patients with obesity-related heart failure with preserved ejection fraction (HFpEP), and decrease the risk of major kidney disease events and cardiovascular-related mortality in patients with type 2 diabetes and chronic kidney disease(Butler et al 2024